Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Eyeing inorganic opportunities to increase growth: Torrent

    • Expect Rs 600-700cr sales from overseas biz: Elder Pharma

    • Looking at a turnover of Rs 200cr from domestic biz: Elder

    • JV with Kose to commence in 3 months: Elder Pharma

      Elder Pharmaceuticals entered into an agreement with Kose Corporation of Japan to form a joint venture (JV) company to manufacture and sell cosmetics in the Indian market. Alok Saxena, director of the company shares details with CNBC-TV18 regarding the JV.

    • Elder Pharma inks pact with Russia's PharmEco

      Elder Pharma today inked an agreement called Memorandum of Understanding (MOU) with Russia's Pharmeco. Alok Saxena, JT MD of Elder Pharma joined CNBC-TV18 to give more information on the same.

    • Bullish on domestic market: Elder Pharma

      In an interview to CNBC-TV18, Alok Saxena, joint managing director of Elder Pharma says, he is bullish on the domestic market. “On the domestic front, we are still growing at about 25%. All our brands are growing at 25%. This segment will continue to be the major growth driver for the company,” he adds.

    • Working to cut debt over next 2 years: Elder Pharma

      Alok Saxena, Director, Elder Pharma in an interview with CNBC-TV18 spoke about the growth plans of the company. The company has completely restrategise the domestic operations in the last few months.

    • Elder Pharma sees 21% growth in domestic formulations ahead

      In an interview with CNBC-TV18, Alok Saxena, Director (International), Elder Pharmaceuticals spoke about the performance of the company. The company is expecting its domestic formulation business to report growth of 20-25% ahead.

    • Bulgarian facility to help jumpstart Elder Pharma's Shelcal into European market

      Alok Saxena, director of Elder Pharma, in an interview with CNBC-TV18’s Latha Venkatesh and Anuj Singh, spoke about the recent happenings in his company and the road ahead.

    • Neutrahealth, euro arm to boost sales in Q4: Elder Pharma

      In an exclusive interview with of Letha Venkatesh and Gautum Broker of CNBC TV 18`s Alok Saxena, Director, Elder Pharmaceuticals said, ``The company is seeing strong growth due to consolidation of Neutrahealth, Also, it is confident of getting positive turnover from Bulgaria in the next financial year.``

    • To buy 1-2% of $70 bn Japanese pharma mkt: Elder

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347